实体器官移植受者的2019冠状病毒病疫苗接种

Q4 Medicine
Y. Wang, Y. Zhou, L. Yang, M. Gou, Y. Bian
{"title":"实体器官移植受者的2019冠状病毒病疫苗接种","authors":"Y. Wang, Y. Zhou, L. Yang, M. Gou, Y. Bian","doi":"10.3760/cma.j.cn114015-20210624-00707","DOIUrl":null,"url":null,"abstract":"Solid organ transplant (SOT) recipients are a high-risk population for coronavirus disease 2019 (COVID-19), and the safety and efficacy of COVID-19 vaccines in this population is of great concern. At present, the published studies on COVID-19 vaccines for SOT recipients are mainly about mRNA vaccines and there are a few cases reports on recombinant adenovirus vector-based vaccines. These results show that the COVID-19 vaccines are safe for the SOT recipients, but the immune response rates are lower and the incidence of vaccine breakthrough infections is higher than that in the general population. Based on the results of the current studies, SOT recipients can start to be vaccinated with COVID-19 vaccines 1 to 3 months after organ transplantation. Prevention of COVID-19 after vaccination is still necessary to avoid vaccine breakthrough infections. Copyright © 2021 by the Chinese Medical Association.","PeriodicalId":7863,"journal":{"name":"药物不良反应杂志","volume":"8 1","pages":"348-351"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Coronavirus disease 2019 vaccination in solid organ transplant recipients\",\"authors\":\"Y. Wang, Y. Zhou, L. Yang, M. Gou, Y. Bian\",\"doi\":\"10.3760/cma.j.cn114015-20210624-00707\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Solid organ transplant (SOT) recipients are a high-risk population for coronavirus disease 2019 (COVID-19), and the safety and efficacy of COVID-19 vaccines in this population is of great concern. At present, the published studies on COVID-19 vaccines for SOT recipients are mainly about mRNA vaccines and there are a few cases reports on recombinant adenovirus vector-based vaccines. These results show that the COVID-19 vaccines are safe for the SOT recipients, but the immune response rates are lower and the incidence of vaccine breakthrough infections is higher than that in the general population. Based on the results of the current studies, SOT recipients can start to be vaccinated with COVID-19 vaccines 1 to 3 months after organ transplantation. Prevention of COVID-19 after vaccination is still necessary to avoid vaccine breakthrough infections. Copyright © 2021 by the Chinese Medical Association.\",\"PeriodicalId\":7863,\"journal\":{\"name\":\"药物不良反应杂志\",\"volume\":\"8 1\",\"pages\":\"348-351\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"药物不良反应杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn114015-20210624-00707\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"药物不良反应杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn114015-20210624-00707","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

实体器官移植(SOT)受者是2019冠状病毒病(COVID-19)的高危人群,COVID-19疫苗在该人群中的安全性和有效性值得关注。目前已发表的SOT受体COVID-19疫苗的研究主要是mRNA疫苗,基于重组腺病毒载体的疫苗报道较少。这些结果表明,COVID-19疫苗对SOT受者是安全的,但免疫应答率较低,疫苗突破感染的发生率高于普通人群。根据目前的研究结果,SOT受者可以在器官移植后1至3个月开始接种COVID-19疫苗。疫苗接种后预防COVID-19仍然是必要的,以避免疫苗突破感染。中华医学会版权所有©2021。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Coronavirus disease 2019 vaccination in solid organ transplant recipients
Solid organ transplant (SOT) recipients are a high-risk population for coronavirus disease 2019 (COVID-19), and the safety and efficacy of COVID-19 vaccines in this population is of great concern. At present, the published studies on COVID-19 vaccines for SOT recipients are mainly about mRNA vaccines and there are a few cases reports on recombinant adenovirus vector-based vaccines. These results show that the COVID-19 vaccines are safe for the SOT recipients, but the immune response rates are lower and the incidence of vaccine breakthrough infections is higher than that in the general population. Based on the results of the current studies, SOT recipients can start to be vaccinated with COVID-19 vaccines 1 to 3 months after organ transplantation. Prevention of COVID-19 after vaccination is still necessary to avoid vaccine breakthrough infections. Copyright © 2021 by the Chinese Medical Association.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
药物不良反应杂志
药物不良反应杂志 Medicine-Pharmacology (medical)
CiteScore
0.20
自引率
0.00%
发文量
3395
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信